Advertisement

Topics

Arrien Pharmaceuticals signs license agreement for psoriasis treatment ARN-6039

19:00 EDT 29 Jun 2017 | Pharmaceutical Technology

Targeted therapeutics drug discovery and development company Arrien Pharmaceuticals has entered a worldwide license agreement with an unnamed US-based pharmaceutical firm for the clinical agent ARN-6039.

Original Article: Arrien Pharmaceuticals signs license agreement for psoriasis treatment ARN-6039

NEXT ARTICLE

More From BioPortfolio on "Arrien Pharmaceuticals signs license agreement for psoriasis treatment ARN-6039"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...